Lanean...
Safety and efficacy of durvalumab (MEDI4736) in various solid tumors
INTRODUCTION: The prominent immune checkpoint molecule, programmed cell death ligand-1 (PD-L1), is the object of increasing attention. Here, we report a meta-analysis investigating the safety and efficacy of durvalumab (MEDI4736), an inhibitor of PD-L1, in various solid tumors. METHODS: A systematic...
Gorde:
| Argitaratua izan da: | Drug Des Devel Ther |
|---|---|
| Egile Nagusiak: | , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Dove Medical Press
2018
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6038862/ https://ncbi.nlm.nih.gov/pubmed/30013326 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S162214 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|